Aphria Inc. announced that it has signed a supply agreement with Australian-based Althea Company Pty Ltd. and invested $2.5 million in Althea in exchange for 25% shareholdings in the company. The investment increases Aphria's presence in the emerging Australian cannabis market. As part of the supply agreement, Aphria will provide Althea with packaged co-branded cannabis oil and dried flower products for the Australian medical cannabis market, further expanding Aphria brand's footprint globally. Althea has already received import permits from the Australian Government's Office of Drug Control (ODC) and Aphria is expected to export the first shipment this month, subject to regulatory approvals by Health Canada. This is the second supply agreement Aphria has entered into with the Australian market as the Company continues to expand its international operations. In October 2017, Aphria announced that it had completed its first shipment of cannabis oil to Australian medical life science company, Medlab Clinical Limited.